Antimicrobial-resistant invasive Escherichia coli, Spain

Surveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates...

Descripción completa

Detalles Bibliográficos
Autores: Oteo-Iglesias, Jesus, Lázaro, Edurne, Abajo Iglesias, Francisco J de, Baquero, Fernando, Campos, Jose
Tipo de recurso: artículo
Fecha de publicación:2005
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/9885
Acceso en línea:http://hdl.handle.net/20.500.12105/9885
Access Level:acceso abierto
Palabra clave:Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Escherichia coli
Escherichia coli Infections
Humans
Prospective Studies
Spain
Time Factors
Drug Resistance, Bacterial
id ES_2644055c4e5d330e976f5fd871eb2835
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/9885
network_acronym_str ES
network_name_str España
repository_id_str
spelling Antimicrobial-resistant invasive Escherichia coli, SpainOteo-Iglesias, JesusLázaro, EdurneAbajo Iglesias, Francisco J deBaquero, FernandoCampos, JoseAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli InfectionsHumansProspective StudiesSpainTime FactorsDrug Resistance, BacterialSurveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates of 59.9%, 32.6%, 19.3%, 6.8%, and 5.3%, respectively. Resistance to multiple drugs increased from 13.8% in 2001 to 20.6% in 2003 (p <0.0001). Antimicrobial consumption data were obtained from the Spanish National Health System. In spite of decreased cephalosporin and beta-lactam use, overall extended-spectrum beta-lactamase production increased from 1.6% (2001) to 4.1% (2003) (p <0.0001), mainly due to the rising prevalence of cefotaximases. Resistance to ciprofloxacin significantly increased, mostly in community-onset infections, which coincided with a rise in community quinolone use. Cotrimoxazole resistance remained stable at approximately 30%, even though its use was dramatically reduced.Centers for Disease Control and Prevention (CDC)Instituto de Salud Carlos IIIUnión Europea. Comisión EuropeaMinisterio de Sanidad y Consumo (España)20202020-05-0520052005-04-0120052005-04-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/9885reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución-NoComercial-CompartirIgual 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/98852026-06-12T12:43:37Z
dc.title.none.fl_str_mv Antimicrobial-resistant invasive Escherichia coli, Spain
title Antimicrobial-resistant invasive Escherichia coli, Spain
spellingShingle Antimicrobial-resistant invasive Escherichia coli, Spain
Oteo-Iglesias, Jesus
Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Escherichia coli
Escherichia coli Infections
Humans
Prospective Studies
Spain
Time Factors
Drug Resistance, Bacterial
title_short Antimicrobial-resistant invasive Escherichia coli, Spain
title_full Antimicrobial-resistant invasive Escherichia coli, Spain
title_fullStr Antimicrobial-resistant invasive Escherichia coli, Spain
title_full_unstemmed Antimicrobial-resistant invasive Escherichia coli, Spain
title_sort Antimicrobial-resistant invasive Escherichia coli, Spain
dc.creator.none.fl_str_mv Oteo-Iglesias, Jesus
Lázaro, Edurne
Abajo Iglesias, Francisco J de
Baquero, Fernando
Campos, Jose
author Oteo-Iglesias, Jesus
author_facet Oteo-Iglesias, Jesus
Lázaro, Edurne
Abajo Iglesias, Francisco J de
Baquero, Fernando
Campos, Jose
author_role author
author2 Lázaro, Edurne
Abajo Iglesias, Francisco J de
Baquero, Fernando
Campos, Jose
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Instituto de Salud Carlos III
Unión Europea. Comisión Europea
Ministerio de Sanidad y Consumo (España)
dc.subject.none.fl_str_mv Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Escherichia coli
Escherichia coli Infections
Humans
Prospective Studies
Spain
Time Factors
Drug Resistance, Bacterial
topic Anti-Bacterial Agents
Drug Resistance, Multiple, Bacterial
Escherichia coli
Escherichia coli Infections
Humans
Prospective Studies
Spain
Time Factors
Drug Resistance, Bacterial
description Surveillance System. A network of 32 Spanish hospitals, serving approximately 9.6 million persons, submitted antimicrobial-susceptibility data on 7,098 invasive Escherichia coli species (2001-2003). Resistance to ampicillin, cotrimoxazole, ciprofloxacin, gentamicin, and tobramycin was found at rates of 59.9%, 32.6%, 19.3%, 6.8%, and 5.3%, respectively. Resistance to multiple drugs increased from 13.8% in 2001 to 20.6% in 2003 (p <0.0001). Antimicrobial consumption data were obtained from the Spanish National Health System. In spite of decreased cephalosporin and beta-lactam use, overall extended-spectrum beta-lactamase production increased from 1.6% (2001) to 4.1% (2003) (p <0.0001), mainly due to the rising prevalence of cefotaximases. Resistance to ciprofloxacin significantly increased, mostly in community-onset infections, which coincided with a rise in community quinolone use. Cotrimoxazole resistance remained stable at approximately 30%, even though its use was dramatically reduced.
publishDate 2005
dc.date.none.fl_str_mv 2005
2005-04-01
2005
2005-04-01
2020
2020-05-05
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/9885
url http://hdl.handle.net/20.500.12105/9885
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-NoComercial-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Centers for Disease Control and Prevention (CDC)
publisher.none.fl_str_mv Centers for Disease Control and Prevention (CDC)
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404811640700928
score 15.811543

Similares en LA Referencia